Rocket Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Rocket is a clinical-stage gene-therapy company with no approved products and no revenue. Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise noted.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $46.4 | $30.8 |
| General and administrative expense | $15.8 | $11.8 |
| Total operating expenses / operating loss | $62.2 | $42.6 |
| Net loss | $58.3 | $43.0 |
| Net loss per share, basic and diluted | $0.73 | $0.67 |
| Net cash used in operating activities | $57.6 | $39.2 |
- Cash and investments: Approximately $360.0 million in cash, cash equivalents and investments at March 31, 2023, versus approximately $399.7 million at December 31, 2022. Cash and cash equivalents alone were $64.6 million; investments totaled $295.5 million.
- Management’s runway estimate: Existing resources expected to fund operating expenses and capital expenditures into the first half of 2025. This is an estimate, not a guarantee.
- Cash flows: Investing activities used $36.7 million, mainly reflecting net investment purchases and $3.0 million of property and equipment purchases. Financing activities provided $18.3 million, principally $17.2 million net from the ATM offering. Cash, cash equivalents and restricted cash declined $75.9 million.
- Debt and leases: The filing reports no conventional borrowing balance. Finance lease liabilities were $21.0 million, alongside $4.4 million of operating lease liabilities. Total liabilities were $55.9 million; stockholders’ equity was $458.9 million.
- Margins: Gross margin is not meaningful because there was no revenue; operating expenses exceeded revenue, resulting in an operating loss.
Changes versus the prior comparable period
- Net loss increased $15.4 million year over year. Operating expenses rose $19.6 million, including a $15.6 million increase in R&D and a $4.1 million increase in G&A.
- Management attributed higher R&D spending mainly to manufacturing and development costs, increased employee compensation and benefits, direct materials, and laboratory supplies. Higher G&A included commercial-preparation costs, staffing and stock-based compensation.
- Other income improved by $4.3 million, primarily due to higher investment-related income and accretion. This partly offset increased operating costs.
- Operating cash use increased $18.3 million. The company raised $17.2 million net through its ATM program during the quarter, issuing approximately 0.9 million shares; cumulative ATM net proceeds through quarter-end were $63.8 million.
Pipeline, outlook and material risks
- Near-term milestones anticipated in the filing: RP-L201 (severe LAD-I) BLA filing in Q2 2023; initial component of the RP-A501 global pivotal study for Danon disease in Q2 2023, subject to FDA discussions; RP-A601 for PKP2-ACM IND submission in Q2 2023; RP-L102 (Fanconi anemia) BLA filing in Q4 2023; and initiation of the RP-L301 (PKD) pivotal Phase 2 trial in Q4 2023. These are forward-looking expectations, not reported outcomes.
- Additional outlook: An IND for the acquired BAG3-DCM program was planned for the first half of 2024. Management expected R&D expenses to increase as programs advance and manufacturing and clinical activity expand; it also expected G&A expenses to rise with staffing and public-company requirements.
- Clinical safety and development uncertainty: In the Danon Phase 1 trial, a patient treated at the higher dose developed progressive heart failure and underwent a heart transplant five months after treatment; the filing describes advanced disease before treatment. Following a TMA safety concern at the higher dose, Rocket said it would focus on the lower dose and had revised safety and immunomodulation measures. The program’s pivotal design and endpoints remained under discussion with the FDA.
- Other clinical disclosures: Rocket reported favorable interim efficacy and safety findings for its Fanconi anemia and LAD-I programs, while acknowledging that a Fanconi anemia patient developed T-cell lymphoblastic lymphoma; tumor testing showed negligible vector marking, and the company stated the lymphoma was not caused by vector insertion. Clinical findings are interim and do not establish approval or commercial success.
- Principal business risks: No product revenue; substantial ongoing R&D needs; clinical, manufacturing and regulatory uncertainty; competition and intellectual-property risks; and dependence on future financing or eventual operating cash generation. Additional equity financing could dilute shareholders. The company reported no material change to the risk factors in its 2022 Form 10-K.
- Contingencies and controls: The company stated it did not believe ordinary-course litigation would reasonably be expected to have a material adverse effect. A New York City audit of biotechnology credits for 2018–2020 remained ongoing. Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting.
Most important facts for investors to verify
- Whether the stated cash-and-investment runway into the first half of 2025 remains supportable as clinical, manufacturing and operating spending evolves.
- Progress and actual timing of the anticipated FDA filings, pivotal-trial starts and IND submission; confirm subsequent regulatory updates rather than relying on the quarter’s projections.
- Updated safety, efficacy and follow-up data across programs, especially the Danon dose strategy and safety monitoring, and the status of the Fanconi anemia lymphoma follow-up.
- Future cash burn, ATM usage, share-count changes and potential dilution; the filing reported 80.4 million common shares outstanding as of May 1, 2023.
- Whether manufacturing capacity, product quality and regulatory alignment support planned pivotal studies and potential commercialization.